Startup · $500k raised
Biotech developing the BEAT platform to unlock CAR-T cell therapy for solid tumours
Melbourne, VIC
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Currus Biologics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator · Grant | - |
Investors whose own portfolio pages list Currus Biologics, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
| Main Sequence Ventures | its portfolio page ↗ |
Companies Currus Biologics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Alessandra Cesano | Chair of the Board | Mirage News, Brandon BioCatalyst portfolio, Uniseed |
| Dr Clare Slaney | BEAT Inventor (former) | Brandon BioCatalyst, Main Sequence |
| Dr Swami Murugappan | Chief Medical Officer | Mirage News, Brandon BioCatalyst portfolio, Uniseed |
| Sam Cobb | CEO | Mirage News, Brandon BioCatalyst portfolio, Uniseed, Brandon BioCatalyst, Main Sequence |
Stories naming Currus Biologics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
America's medicines regulator has approved Currus Biologics to begin human trials of CUR-001, its solid-tumour CAR T-cell therapy combination, with dosing expected from early 2027.
Australian biotech Currus Biologics has won US regulator clearance to begin human testing of its lead cancer therapy, CUR-001; the company's backers include Brandon Capital, Main Sequence and Uniseed.
Australian biotech Currus Biologics has won US regulatory clearance to begin human testing of its lead cancer therapy, CUR-001, combining an antibody platform with CAR T cells for solid tumours.
Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.
Also australiatimes.com
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.
Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.
Ignition Lane's weekly technology roundup: climate-tech funding activity, Grok's bid for AGL, King River Capital's digital asset fund, a batch of Australian startup raises, Maropost acquisitions, GigSuper's collapse and a National AI Centre appointment.